跳至主要内容
临床试验/NCT03384485
NCT03384485Unknown不适用

Prevalence of Lysosomal Hydrolase Alpha-glagtosidase Deficiency in Patients

Meir Medical Center2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2018年2月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
100
试验地点
2
主要终点
Lys-3-3 plasma

研究概览

简要总结

Fabry disease, an X-linked disorder of glycosphingolipids that is caused by mutations of the GLA gene that codes for α-galactosidase A, leads to dysfunction of many cell types and includes a systemic vasculopathy. As a result, patients have a markedly increased risk of developing ischemic stroke, small-fiber peripheral neuropathy, cardiac dysfunction and chronic kidney disease. Because this disease is a rare disease most of the time it is misdiagnosed, so in this study we will check out the Prevalence of lysosomal hydrolase alpha-glagtosidase deficiency ( Fabry disease) in patients with Antiphospholipid Syndrome.

详细描述

the investigators would like to assess the prevalence of Fabry in men and women aged 18-100 who were diagnosed with antiphospholipid syndrome in our departmental clinic in 2000-2017 It is very important to diagnose Fabri that then the treatment of patients can vary dramatically.

The study will include 100 adult patients (18-100) men and women. Testing for the Fabri test in men is an enzyme test and will be performed subject to their consent to sign informed consent. In the women, an enzyme test will be carried out, and the plasma Lys-3-3 plasma storage, as recommended in the recently published diagnostic algorithms, is examined. If diagnosed, a patient will be referred to a genetic institute for further genetic counseling

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of Antiphospholipid syndrome.
  • able to read and sign inform concent

排除标准

  • Fabry disease.

研究组 & 干预措施

antiphospholipid syndrome

Other

blood test in patients that diagnosed with antiphospholipid syndrome to diagnose Fabry's disease

干预措施: antiphospholipid syndrome (Diagnostic Test)

结局指标

主要结局

Lys-3-3 plasma

时间窗: an average of 1 year

blood test to find the enzyme for Fabry's disease

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

yair levy

head of department internal medicine E

Meir Medical Center

研究点 (2)

Loading locations...

相似试验